China's National Medical Products Administration (NMPA) approved fully digital Drug Manufacturing License system, set to become fully operational by January 1st, 2026.
The reform, part of the Country's "Digital Government" initiative, replaces paper licenses with QR-code-based digital versions that provide real-time updates on manufacturing data. This development enhances transparency, strengthens compliance, protects third parties, and streamlines regulatory processes for all domestic drug manufacturers.